Ac Immune Sa Stock News

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau,

AC Immune SA (NASDAQ: ACIU ) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ ), have found that an early-stage Alzheimer''s vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group … Full story available on Benzinga.com

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau,

AC Immune (ACIU) reported interim 10-week data from a high-dose cohort of a phase 1b/2a trial evaluating ACI-35.030, a phosphorylated-Tau (pTau) vaccine candidate in people with…

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or high-dose cohorts to date Interim data support plans for further late-stage development LAUSANNE, Switzerland, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced new interim 10-week data from the high-dose cohort of a placebo-controlled Phase 1b/2a trial evaluating ACI-35.030, a first-in-class phosphorylated-Tau (pTau) vaccine candidate in participants with early Alzheimer''s disease (AD). The Company previously reported interim data from low-dose and mid-dose cohorts. ACI-35.030, based on AC Immune''s SupraAntigen ® platform, is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain.

AC Immune will advance an optimized version of ACI-24, currently in preclinical stage, into the clinic for Alzheimer''s disease.

Futures Reverse Overnight Gains As Amazon Euphoria Fizzles We warned last night that the surge in futures following the huge bounce in Amazon stock wouldn''t last (simply because a closer read of the company''s earnings left a lot to be desired) and sure enough, in the overnight (extremely illiquid) session, 500 futures erased gains of as much as 1.3% to trade 0.1% lower, or 10 points, to 4,460 as European stocks extend their decline as inflation and monetary tightening outweighed earnings optimism. Meanwhile, Nasdaq 100 futures pared much of their gains, trading just 0.5% higher after earlier rising more than 2%, one day after the index had the worst day since September 2020. The VIX increased for a third day Friday, hovering just below 26. The dollar dropped as the EUR surge continued, following yesterday''s unexpectedly hawkish comments from Lagarde ... while oil was on course for a seventh weekly advance with Brent rising Relief, as brief as it was, was welcome after a 4.2% crash in the Nasdaq 100 Index on Thursday, its biggest since 2020, fueled by a 26% rout in Meta Platforms following disappointing results.

Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development

LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ann

Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD)

Wells Fargo & Company MN grew its stake in AC Immune SA (NASDAQ:ACIU) by 4.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 335,104 shares of the company’s stock after acquiring an additional 14,175 shares during the period. Wells Fargo & Company MN owned about 0.46% […]

Equities analysts predict that AC Immune SA (NASDAQ:ACIU) will announce $46.37 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for AC Immunes earnings. The highest sales estimate is $89.65 million and the lowest is $3.08 million. AC Immune reported sales of $1.05 million in the same quarter last []

AC Immune SA (NASDAQ:ACIU) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 608,900 shares, a decrease of 50.9% from the October 31st total of 1,240,000 shares. Based on an average trading volume of 2,190,000 shares, the short-interest ratio is []